Olema Pharmaceuticals, Inc. · NASDAQ:OLMA
BVF PARTNERS L P/IL reported a 9.80% stake in Olema Pharmaceuticals, Inc. (Schedule 13D/A)
Event Oct 14, 2026 · Filed Oct 16, 2026
BVF PARTNERS L P/IL reported a 9.80% stake in Olema Pharmaceuticals, Inc., 8,939,731 shares, with active intent on Oct 14, 2026. Filed Oct 16, 2026 (Schedule 13D/A).
- Stake
- 9.80%
- Shares
- 8,939,731
- Intent
- Active
- What changed
- Stake changed
- Filed together
- 11 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| BIOTECHNOLOGY VALUE FUND L P | 6.60% | 5,946,981 |
| BVF I GP LLC | 6.60% | 5,946,981 |
| BIOTECHNOLOGY VALUE FUND II LP | 2.70% | 2,356,800 |
| BVF II GP LLC | 2.70% | 2,356,800 |
| Biotechnology Value Trading Fund OS LP | 0.40% | 347,970 |
| BVF Partners OS Ltd. | 0.40% | 347,970 |
| BVF GP HOLDINGS LLC | 9.10% | 8,303,781 |
| BVF PARTNERS L P/IL | 9.80% | 8,939,731 |
| BVF INC/IL | 9.80% | 8,939,731 |
| LAMPERT MARK N | 9.80% | 8,939,731 |
| Hrustanovic Gorjan | 0.20% | 183,645 |
Source
Download original · View original at SEC
Related
- Olema Pharmaceuticals, Inc.
- Bvf Partners L P
- Olema Pharmaceuticals, Inc. shareholders
- Schedule 13G/A · FMR LLC · Aug 6, 2026
- Schedule 13G/A · BlackRock, Inc. · Jul 29, 2026
- Form 4 · Harmon Cyrus · Jul 27, 2026
- Schedule 13G/A · Bain Capital Life Sciences Opportunities IV, L.P. · May 15, 2026
- Schedule 13G/A · Janus Henderson Group PLC · May 15, 2026